VK Patel, E Shirbhate, P Patel, R Veerasamy… - Beni-Suef University …, 2021 - Springer
Abstract Background The World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is …
Several drugs and antibodies have been repurposed to treat COVID-19. Since the outcome of the drugs and antibodies clinical studies have been mostly inconclusive or with lesser …
S Lu, Q Zhou, L Huang, Q Shi, S Zhao… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Glucocorticoids are widely used in the treatment of various pulmonary inflammatory diseases, but they are also often accompanied by significant adverse …
Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in …
S Bruscoli, PG Puzzovio, M Zaimi, K Tiligada… - Pharmacological …, 2022 - Elsevier
Abstract Coronavirus Disease 19 (COVID-19) is associated with high morbidity and mortality rates globally, representing the greatest health and economic challenge today. Several …
The wide and rapid spread of the COVID-19 pandemic has placed an unanticipated burden on the global healthcare sector. This necessitated a swift response from the international …
Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health …
T Kino, I Burd, JH Segars - International journal of molecular sciences, 2021 - mdpi.com
The coronavirus disease 2019 (COVID-19) caused by infection of the severe respiratory syndrome coronavirus-2 (SARS-CoV-2) significantly impacted human society. Recently, the …
Y Hu, T Wang, Z Hu, X Wang, Z Zhang, L Li… - Biomedicine & …, 2020 - Elsevier
The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical …